Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice

Yutao Xia, Mingfang Wang, Taosheng Huang, Kai Sun, Peng Wang

Open source

DOI
10.3389/fonc.2026.1910011
Published
2026-08-26
Container
Frontiers in Oncology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1910011,
  title = {Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice},
  author = {Yutao Xia and Mingfang Wang and Taosheng Huang and Kai Sun and Peng Wang},
  year = {2026},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2026.1910011},
  url = {https://doi.org/10.3389/fonc.2026.1910011}
}

RIS

TY  - JOUR
TI  - Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice
AU  - Yutao Xia
AU  - Mingfang Wang
AU  - Taosheng Huang
AU  - Kai Sun
AU  - Peng Wang
PY  - 2026
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1910011
UR  - https://doi.org/10.3389/fonc.2026.1910011
ER  - 

APA

Xia, Y., Wang, M., Huang, T., Sun, K., & Wang, P. (2026). Resistance mechanisms and countermeasures in CLDN18.2-positive tumors: from molecular networks to clinical practice. Frontiers in Oncology. https://doi.org/10.3389/fonc.2026.1910011

Source records